Now that a federal appeals court in Washington, D.C., has heard arguments in Novartis and United Therapeutics’ 340B contract pharmacy lawsuits, the scene shifts to Chicago, where an appeals court will hear arguments Monday morning in Eli Lilly’s companion case.
…
Two of three judges on a federal appeals court panel yesterday repeatedly asked lawyers during a highly anticipated hearing in Washington, D.C., what standard the court should use to decide whether drug manufacturers’ 340B contract pharmacy conditions are legal.
The
…
The federal government and a Tennessee health system are meeting with a mediator in connection with a whistleblower lawsuit that alleges that the system paid Memphis-area cancer physicians for referrals that generated $50 million in profits in one year alone
…
Two of three judges on a federal appeals court panel strongly indicated this morning that they reject the federal government’s position that nothing in the 340B statute gives drug manufacturers the right to put any conditions on offers of 340B
…
The U.S. Health Resources and Services Administration yesterday referred drug manufacturer Merck to the Department of Health and Human Services Office of Inspector General for possible imposition of civil fines over Merck’s 340B contract pharmacy restrictions.
Public Health Services Lt.
…
The U.S. Centers for Medicare & Medicaid Services is making computer file changes to restore hospitals’ Part B payments for 340B-purchased drugs to average sales price plus 6% for the rest of 2022 after paying them almost 30% less since
…
Pharmaceutical manufacturer contractor Kalderos has replaced Review, its 340B drug claims verification tool, with a new one named Discount Hub.
Chicago-based Kalderos announced the change in an Aug. 31 blog post and an Oct. 12 news release. It said Discount Hub
…
The National Association of Community Health Centers is asking to meet with U.S. Health and Human Services Secretary Xavier Becerra to discuss drug companies’ “unlawful restrictions” on 340B drug shipments to contract pharmacies.
NACHC told Becerra in an Oct. 14
…
Federal health officials told drug manufacturers AbbVie and Amgen late yesterday their restrictions on 340B pricing when providers use contract pharmacies are illegal and must end or the companies could be fined.
The Health Resources and Services Administration’s last 340B
…
More than 1,000 covered entities—double the number in May—are submitting 340B drug claims data to Second Sight Solutions’ 340B ESP platform to be able to keep dispensing manufacturers’ drugs to patients at multiple contract pharmacies, a senior 340B ESP leader
…*Sign up for news summaries and alerts from 340B Report